Dr Lowentritt on PSA Response and Time to Castration Resistance in mCSPC
April 29th 2023
Benjamin H. Lowentritt, MD, FACS, discusses prostate-specific antigen response and time to castration resistance in patients with metastatic castration-sensitive prostate cancer started on apalutamide, enzalutamide, or abiraterone acetate.